[First Release] Rui Long Surgical Secures Over $100 Million in Financing, Partners with Johnson & Johnson for Strategic Collaboration
VCBeat has exclusively learned that Ronovo Surgical, a global innovator in next-generation modular surgical robotics, announced today the completion of its Series D financing round led by Johnson & Johnson Development Corporation (JJDC), with participation from Lilly Asia Ventures (LAV), INCE CAPITAL, LTD., and Granite Asia. The total funding amount reached $67 million.
This round of financing is another significant funding for RuiLong Surgical following the Series C round led by Granite Asia in early 2025. The company's total financing from January to September 2025 exceeded 100 million US dollars, reflecting the high recognition by top global healthcare investment institutions of RuiLong Surgical’s development and potential, as well as their firm confidence in promoting the widespread adoption of robotic minimally invasive surgery worldwide.
Upon completing its Series D financing, RuiLong Surgical entered into a strategic cooperation agreement with Johnson & Johnson MedTech. The two parties will combine RuiLong Surgical's HaiShanYi...®The modular advantages of the endoscopic surgical robot system combined with Johnson & Johnson Medical’s leading technology in the field of minimally invasive surgery provide medical institutions in certain regions of China with a richer array of digital minimally invasive surgical solutions.
The HAI SHAN YI® platform obtained registration approval from the China National Medical Products Administration (NMPA) in March 2025, becoming the first modular surgical robot platform to be approved in China. It is also the first laparoscopic surgical robot system in China to receive initial registration approval for four major clinical specialties: general surgery, gynecology, urology, and thoracic surgery. With its differentiated advantages of being "modular, dexterous, and configurable," HAI SHAN YI® aims to address numerous challenges faced by traditional laparoscopic robotic systems in terms of flexibility, accessibility, and affordability.
In addition to accelerating its commercial deployment in the Chinese market, Ronovo Surgical is also rapidly advancing its global strategy, having initiated the registration and application process for Haishanyi® in Europe and South America. Its unique competitive differentiators and clinical value have garnered widespread acclaim from internationally renowned clinical experts, demonstrating strong international recognition and application potential. The company is well-positioned to address unmet clinical needs across different global regions, further promoting the worldwide adoption of robotic minimally invasive surgical procedures.
Dr. Changzheng Ma, founder, chairman, and CEO of Ruilong Surgical, stated: "We are very grateful to JJDC for leading the D-round financing and thank all our new and old shareholders for their recognition and support.®The modular, dexterous, and configurable design of the endoscopic surgical robot represents Ruilong Surgical's firm belief in the global popularization of robotic minimally invasive surgery. We are delighted to strategically collaborate with Johnson & Johnson Medical Technologies to accelerate HaiShan One.®"In the commercialization process in China, better serve China, and lay a solid foundation for Ruilong Surgical's global layout."
Recommended Reading: